Young Joseph R 4

What Happened

• Joseph R. Young, Senior Vice President, Finance and Chief Accounting Officer of Vera Therapeutics, exercised options on March 13, 2026 to acquire 10,000 shares at a $3.94 strike price for a cash outlay of $39,396. The filing also shows a contemporaneous disposition of 10,000 shares reported at $0 (derivative). Both transactions are reported as code M (option exercise).

Key Details

• Transaction date: 2026-03-13; Filing date: 2026-03-16 (filed within the required reporting window).
• Exercise: 10,000 shares acquired at $3.94 per share — total cost $39,396.
• Disposition: 10,000 shares reported disposed at $0.00 (listed as a derivative disposition; proceeds $0).
• Shares owned after the reported transactions: not specified in the filing.
• Footnotes: F1 notes inclusion of 1,032 shares acquired pursuant to the Company’s 2021 Employee Stock Purchase Plan; F2 describes vesting (1/4 vested March 9, 2022, then 1/48 monthly thereafter).
• Transaction code: M = Option exercise. No 10b5-1 plan or late filing flag was indicated.

Context

• This filing documents an option exercise (a purchase of shares by the insider). The separate line showing a $0.00 disposition commonly reflects shares surrendered to the company (for example, to cover taxes or exercise costs) rather than an open-market sale; the Form 4 does not spell out the reason. Because no cash sale of shares is shown, this is not evidence that the insider sold shares for proceeds.